Table 1.
Mean Demographic Characteristics for Healthy Volunteers (HV) and Patients (SCZ)
| Demographics | HV (n = 27) | SCZ (n = 16) | ||
|---|---|---|---|---|
| Age (years) | 43.5±15.5 | 42.5±14.0 | F = 0.263, P = .611 | |
| Gender | Male/female | 10/17 | 10/6 | Χ 2 = 2.618, P = .106 |
| Genotype | HAB/MAB/LAB | 19/8/0 | 10/6/1 | Χ 2 = 1.904, P = .386 |
| PET measures | Amount injected (mCi) | 4.81±0.36 | 4.79±0.84 | F = 0.027, P = .869 |
| Specific activity (mCi/µmol) | 4071.7±3622.0 | 3589.9±1492.7 | F = 0.426, P = .518 | |
| Mass injected (µg) | 0.91±0.76 | 0.80±0.63 | F = 2.19, P = 0.149 | |
| Age at SCZ onset | 29.1±8.3 | |||
| Number of episodes | 7.3±11.7 | |||
| Length of untreated illness (months) | 43.4±63.0 | |||
| Length of illness (months) | 177.3±105.7 | |||
| CDS | 3.8±2.9 | |||
| AES | 33.8±8.0 | |||
| PANSS | Total | 70.2±9.7 | ||
| Positive | 19.3±2.2 | |||
| Negative | 18.6±5.0 | |||
| General | 31.6±6.3 | |||
| RBANS | Total | 76.3±18.2 | ||
| Immediate memory | 81.9±22.9 | |||
| Visuospatial ability | 79.8±21.5 | |||
| Language | 83.9±20.1 | |||
| Attention | 75.4±14.5 | |||
| Delayed memory | 84.8±19.1 | |||
| Treatment | Typical antipsychotics | 2 | ||
| Atypical antipsychotics | 14 | |||
| Antidepressants | 5 | |||
| Clonazepam | 7 | |||
| Anti-Parkinsonian agents | 2 | |||
| CPZ equivalents | 300.0±237.0 |
Note: AES, Apathy Evaluation Scale; CDS, Calgary Depression Scale; CPZ, chlorpromazine; HAB, high-affinity binder; LAB, low-affinity binder; MAB, mixed-affinity binder; PANSS, Positive and Negative Syndrome Scale; PET, positron emission tomography; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; SCZ, schizophrenia.